Teva announced the launch of AirDuo® Digihaler® (fluticasone propionate and salmeterol inhalation powder) and ArmonAir® Digihaler® (fluticasone propionate inhalation powder) for patients with asthma.

AirDuo Digihaler is a combination of fluticasone propionate, a corticosteroid, and salmeterol, a long-acting beta2-adrenergic agonist (LABA). It should be used in patients 12 years of age and older not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and LABA.

ArmonAir Digihaler contains fluticasone, a corticosteroid. It is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years and older.

Both products contain a built-in electronic module that detects, records and stores data on inhaler events, including peak inspiratory flow rate (L/minute), for transmission to the Digihaler® app where inhaler events are categorized. Using the app, patients can then review and share data with their health care providers, as well as schedule dosing reminders; use of the app is not required for administration. 


Continue Reading

The AirDuo Digihaler is supplied in 3 strengths: 55/14mcg, 113/14mcg, and 232/14mcg; each inhaler provides 60 actuations. The Wholesale Acquisition Cost (WAC) is $399 for the 55mcg/14mcg and 113mcg/14mcg doses and $449 for the 232mcg/14mcg dose. 

The ArmonAir Digihaler is supplied in 3 strengths: 55mcg, 113mcg, and 232mcg; each inhaler provides 60 actuations. The WAC is $239 for the 55mcg and 113mcg doses and $299 for the 232mcg dose.

Related Articles

Teva recently announced the availability of ProAir® Digihaler® for patients aged 4 years and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. The Company has also introduced a patient savings program for the Digihaler portfolio of products.

For more information visit tevapharm.com.

Reference

Teva launches two digital inhalers in the US, AirDuo® Digihaler® (fluticasone propionate and salmeterol) inhalation powder and ArmonAir® Digihaler® (fluticasone propionate) inhalation powder. https://www.businesswire.com/news/home/20200921005170/en/Teva-Launches-Two-Digital-Inhalers-in-the-U.S.-AirDuo%C2%AE-Digihaler%C2%AE-fluticasone-propionate-and-salmeterol-Inhalation-Powder-and-ArmonAir%C2%AE-Digihaler%C2%AE-fluticasone-propionate-Inhalation-Powder. Accessed September 21, 2020.